The global flow cytometry market is estimated to reach $7 billion by 2022, registering a CAGR of 16.0% over the forecast period 2014?2022. Flow cytometry is a biophysical, laser-based analytical technology that measures and analyzes several physical characteristics of cells or particles suspended in a fluid, when passed through a laser beam. Flow cytometry has various advantages over traditional analytical methods such as ELISA, which includes its ability to deliver precise and accurate results, and lesser time consumption at about same prices. The flow cytometry technology is widely used in various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV, and hematological malignancies. The rising count of patients suffering from HIV and cancer, and increasing use of flow cytometry in hospitals and diagnostic centers, has created an impending need for flow cytometry in the effective diagnosis as well as monitoring of diseases. The term flow cytometry as well as fluorescence-activated cell sorting are often interchangeable. FACS or fluorescence activated cell sorting used in flow cytometry have ensured a strong market future.
1.1 Company Overview
1.2 Company Snapshot
1.3 Operating Business Segment
1.4 Business Performance
1.5 Key Strategic moves and Development
FIG. 1. EBIOSCIENCE SEGMENTS, REVENUE 2012-2014 ($MILLION)
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers